13F-HR filed by GREAT POINT PARTNERS LLC
GREAT POINT PARTNERS LLC filed this 13F-HR for the quarter ended 2026-09-30, accepted by EDGAR 2026-11-16 21:15:48 UTC, with 45 holding rows worth $418,469,943.
- Accession
- 0001172661-26-005345
- Filer
- CIK 1281446
- Filed
- 2026-11-16
- Accepted by EDGAR
- Ingested
- Source
- EDGAR live feed
13F report for Q3 2026
A holdings report, 45 entries on the cover page, a total value of $418,469,943 stated on the cover page (in dollars after the unit check, H1), rows summing to $418,469,943 with VALUE read as dollars as filed, 13F file number 028-11743. The quarter's positions are built on this report. The resolved quarter.
Other managers
- included managerJAY JEFFREY R028-12517
- included managerNordahl Lillian028-24470
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| IMMUNITYBIO INC | 45256X103 | COM | 3,000,800 | $28,327,552 | dollars as filed | put |
| VERA THERAPEUTICS INC | 92337R101 | COMMON STOCK | 808,717 | $26,113,472 | dollars as filed | |
| VOR BIOPHARMA INC | 929033207 | COMMON STOCK | 1,126,910 | $21,501,443 | dollars as filed | |
| AMYLYX PHARMACEUTICALS INC | 03237H101 | COM | 700,000 | $20,370,000 | dollars as filed | |
| SAGIMET BIOSCIENCES INC A | 786700104 | COMMON STOCK | 1,961,701 | $19,381,606 | dollars as filed | |
| DEFINIUM THERAPEUTICS INC | 24477V105 | COM SHS | 508,735 | $19,362,454 | dollars as filed | |
| IONIS PHARMACEUTICALS INC COM | 462222100 | Stock | 420,000 | $18,753,000 | dollars as filed | |
| GENMAB A/S | 372303206 | Ordinary Shares, nominal value DKK 1 per share | 525,000 | $18,729,375 | dollars as filed | |
| SOL-GEL TECHNOLOGIES LTD | M8694L137 | SHS NEW | 239,159 | $17,764,731 | dollars as filed | |
| ZURA BIO LTD | G9TY5A101 | COMMON STOCK | 4,077,256 | $16,961,385 | dollars as filed | |
| LB PHARMACEUTICALS INC | 50180M108 | COMMON STOCK | 410,420 | $15,751,920 | dollars as filed | |
| ABIVAX SA- | 00370M103 | SPONSORED ADS | 155,000 | $15,348,100 | dollars as filed | |
| ANNEXON INC | 03589W102 | COM | 3,500,000 | $14,805,000 | dollars as filed | |
| BELITE BIO INC | 07782B104 | CMN | 75,000 | $12,736,500 | dollars as filed | |
| EUPRAXIA PHARMACEUTICALS INC | 29842P105 | COM 298736 AL 3 EURONET WORLDWIDE INC NOTE 0.750% 3/1 | 1,200,000 | $10,920,000 | dollars as filed | |
| NEKTAR THERAPEUTICS | 640268306 | COMMON STOCK | 175,000 | $10,595,375 | dollars as filed | |
| MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD | 61559X104 | Stock | 855,813 | $10,013,012 | dollars as filed | |
| CLIMB BIO INC | 28658R106 | COMMON STOCK | 800,000 | $9,176,000 | dollars as filed | |
| ABCELLERA BIOLOGICS INC COM | 00288U106 | Stock | 600,000 | $8,754,000 | dollars as filed | |
| NEUROGENE INC | 64135M105 | COMMON STOCK | 300,000 | $8,346,000 | dollars as filed | |
| COMPASS PATHWAYS PLC | 20451W101 | SPONSORED ADS | 500,000 | $6,220,000 | dollars as filed | |
| JATT II ACQUISITION CORP | G50765109 | ORD SHS | 500,000 | $5,622,500 | dollars as filed | |
| Inflarx Nv | N44821101 | COM | 3,046,557 | $5,483,803 | dollars as filed | |
| Research Alliance Corp Iii Ord Shs Cl A | G75226103 | Common Stock | 504,891 | $5,467,970 | dollars as filed | |
| BRIGHT MINDS BIOSCIENCES INC | 10919W405 | COMMON STOCK | 109,603 | $5,460,421 | dollars as filed | |
| AMANAT ACQUISITION CORP | G0375M101 | CL A ORD | 500,000 | $5,340,000 | dollars as filed | |
| ALTIMMUNE INC | 02155H200 | COM NEW | 1,741,232 | $4,979,924 | dollars as filed | |
| JATT III ACQUISITION CORP | G5080G109 | COM | 450,000 | $4,959,000 | dollars as filed | |
| PHARVARIS NV | N69605108 | COMMON STOCK | 150,000 | $4,758,000 | dollars as filed | put |
| SCYNEXIS INC | 811292309 | COM | 944,292 | $4,664,802 | dollars as filed | |
| CULLINAN THERAPEUTICS INC | 230031106 | COM | 300,000 | $4,605,000 | dollars as filed | |
| CONTINEUM THERAPEUTICS INC CL A | 21217B100 | Stock | 300,000 | $4,026,000 | dollars as filed | call |
| CYBIN INC | 23256X407 | COM NEW | 320,952 | $3,944,500 | dollars as filed | |
| REZOLUTE INC | 76200L309 | COMMON STOCK | 951,809 | $3,940,489 | dollars as filed | |
| OPUS GENETICS INC | 67577R102 | COMMON STOCK | 776,881 | $3,760,104 | dollars as filed | |
| ENLIVEN THERAPEUTICS INC COM | 29337E102 | Stock | 70,000 | $3,208,800 | dollars as filed | |
| RELMADA THERAPEUTICS INC | 75955J402 | COMMON STOCK | 842,106 | $3,174,740 | dollars as filed | |
| DBV TECHNOLOGIES S A | 23306J309 | SPONSORED ADS | 250,000 | $2,940,000 | dollars as filed | |
| EVOMMUNE INC | 30054Y107 | COMMON STOCK | 325,000 | $2,684,500 | dollars as filed | |
| CONTINEUM THERAPEUTICS INC CL A | 21217B100 | Stock | 186,183 | $2,498,576 | dollars as filed | |
| ORUKA THERAPEUTICS INC COM | 687604108 | Stock | 24,649 | $2,053,015 | dollars as filed | |
| HUMACYTE INC | 44486Q103 | COM | 3,750,000 | $1,941,375 | dollars as filed | |
| REIN THERAPEUTICS INC | 00887A204 | COM NEW | 1,663,144 | $1,337,168 | dollars as filed | |
| RESEARCH ALLIANCE CORP IV | G75228109 | CL A ORD SHS | 106,396 | $1,276,752 | dollars as filed | |
| ANNEXON INC | 03589W102 | COM | 97,300 | $411,579 | dollars as filed | call |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001172661-26-005345 | this filing | 2026-11-16 |